Accès gratuit
Med Sci (Paris)
Volume 20, Numéro 11, Novembre 2004
Page(s) 999 - 1003
Section M/S revues
Publié en ligne 15 novembre 2004
  1. Silverstein AM. History of immunology. In : Paul WE, ed. Fundamental immunology. New York : Raven Press, 1984 : 23–40.
  2. Casadevall A, Scharff MD. Return to the past : the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995; 21 : 150–61.
  3. Lister PD. Emerging resistance problems among respiratory tract pathogens. Am J Manag Care 2000; 6 : S409–18.
  4. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109 : 1001–4.
  5. Hammarström L, Gardulf A, Hammarström V, et al. Systemic and topical immunoglobulin treatment in immunocompromised patients. Immunol Rev 1994; 139 : 43–70.
  6. Enarson DA, Chretien J. Epidemiology of respiratory infectious diseases. Curr Opin Pulm Med 1999; 5 : 128–35.
  7. Reynolds HY. Normal and defective respiratory host defenses. In : Pennington JE, ed. Respiratory infections. New York : Raven Press, 1994 : 1–33.
  8. Lamari F, Karamanos NK, Papadopoulou-Alataki E, et al. Monitoring of two intravenous immunoglobulin. Preparations for immunoglobulin G subclasses and specific antibodies to bacterial surface antigens and relation with their levels in treated immunodeficient patients. J Pharm Biomed Anal 2000; 22 : 1029–36.
  9. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The respiratory syncytial virus immune globulin study group. N Engl J Med 1993; 329 : 1524–30.
  10. Baker JC, Melish ME, Hall RT, et al. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The multicenter group for the study of immune globulin in neonates. N Engl J Med 1992; 327 : 213–9.
  11. Fanaroff AA, Korones SB, Wright LL, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National institute of child health and human development neonatal research network. N Engl J Med 1994; 330 : 1107–13.
  12. Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS clinical trials group. N Engl J Med 1994; 331 : 1181–7.
  13. Douzinas EE, Pitaridis MT, Louris G, et al. Prevention of infection in multiple trauma patients by high dose intravenous immunoglobulins. Crit Care Med 2000; 28 : 8–15.
  14. Conti DJ, Freed BM, Gruber SA, Lempert N. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin. Arch Surg 1994; 129 : 443–7.
  15. Granström M, Olinder-Nielsen AM, Holmblad P, et al. Specific immunoglobulin for treatment of whooping cough. Lancet 1991; 338 : 1230–3.
  16. De Hennezel L, Ramisse F, Binder P, et al. Effective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model. Antimicrob Agents Chemother 2001; 45 : 316–8.
  17. Weltzin R, Monath TP. Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev 1999; 12 : 383–93.
  18. Zeitlin L, Cone RA, Whaley KJ. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg Infect Dis 1999; 5 : 54–64.
  19. Ma JK, Hunjan M, Smith R, et al. An investigation into the mechanism of protection by local passive immunization with monoclonal antibodies against Streptococcus mutans. Infect Immun 1990; 58 : 3407–14.
  20. Ramisse F, Deramoudt FX, Szatanik M, et al. Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab’)2 fragments. Clin Exp Immunol 1998; 111 : 583–7.
  21. Mazanec MB, Kaetzel CS, Lamm ME, et al. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA 1992; 89 : 6901–5.
  22. Lombry C, Edwards DA, Preat V, Vanbever R. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Physiol Lung Cell Mol Physiol 2004; 286 : L1002–8.
  23. Ramisse F, Szatanik M, Binder P, Alonso JM. Passive local immunotherapy of experimental staphylococcal pneumonia with human intravenous immunoglobulin. J Infect Dis 1993; 168 : 1030–3.
  24. Ramisse F, Binder P, Szatanik M, Alonso JM. Passive and active immunotherapy of experimental pneumococcal pneumonia by polyvalent human immunoglobulin or F(ab’)2 fragments administered intranasally. J Infect Dis 1996; 173 : 1123–8.
  25. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Ann Rev Immunol 1994; 12 : 433–55.
  26. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000; 355 : 735–40.
  27. Weltzin R, Traina-Dorge V, Soike K, et al. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis 1996; 174 : 256–61.
  28. Johnson S, Griego SD, Pfarr DS, et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies : MEDI-493 and RSHZ19. J Infect Dis 1999; 180 : 35–40.
  29. Gavilondo JV, Larrick JW. Antibody engineering at the millenium. Biotechniques 2000; 29 : 128–45.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.